Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel-Reference-Cited by-同舟云学术

Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel

Published:2022-06-24 Issue:9 Volume:27 Page:1477-1486
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Narita Shintaro^ORCID,Kimura Takahiro,Hatakeyama Shingo,Hata Kenichi,Yanagisawa Takafumi,Maita Shinya,Chiba Shuji,Sato Hiromi,Kashima Soki,Koizumi Atsushi,Yamamoto Ryohei,Takayama Koichiro,Okane Katsumi,Ishida Toshiya,Horikawa Yohei,Kumazawa Teruaki,Shimoda Jiro,Suzuki Takehiro,Ohyama Chikara,Egawa Shin,Habuchi Tomonori

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-022-02203-y.pdf

Reference33 articles.

1. Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953. https://doi.org/10.1002/ijc.31937

2. Mosillo C, Iacovelli R, Ciccarese C et al (2018) De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treat Rev 70:67–74. https://doi.org/10.1016/j.ctrv.2018.08.005

3. Gaylis FD, Choi JE, Hamilton Z et al (2017) Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. Urol Oncol 35(11):663.e661-663.e667. https://doi.org/10.1016/j.urolonc.2017.06.059

4. Chen R, Ren S, Yiu MK et al (2014) Prostate cancer in Asia: A collaborative report. Asian J Urol 1(1):15–29. https://doi.org/10.1016/j.ajur.2014.08.007

5. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373(8):737–746. https://doi.org/10.1056/NEJMoa1503747

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort;Cancers;2023-09-29

2. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis;Clinical Genitourinary Cancer;2023-09

3. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer;Clinical Genitourinary Cancer;2023-08

4. Trends in the use of local intervention for metastatic hormone‐naïve prostate cancer: A multicenter retrospective study;International Journal of Urology;2023-07-05

5. Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy;The Prostate;2023-01-20